시장보고서
상품코드
1150074

세계의 류마티스 관절염 시장 점유율, 규모, 동향, 산업 분석 리포트 : 치료법별, 유통 채널별, 약제 유형별, 지역별, 부문 예측(2022-2030년)

Rheumatoid Arthritis Market Share, Size, Trends, Industry Analysis Report, By Therapy (Cell Therapy, DMARD, Symptomatic Treatment, Intermediate Corticosteroid Therapies); By Distribution Channel; By Drug Type; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 류마티스 관절염 시장 규모는 2030년까지 333억 달러에 달할 것으로 예측되고 있습니다.

세계의 류마티스 관절염 시장에 대해 조사분석했으며, 시장 역학, 부문 분석, 지역 분석, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 리포트 설명
    • 조사 목적
    • 시장 범위
    • 전제조건
  • 이해관계자

제2장 주요 요약

  • 시장 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 데이터 소스
    • 1차 소스
    • 2차 소스

제4장 세계의 류마티스 관절염 시장 인사이트

  • 류마티스 관절염 : 업계의 스냅숏
  • 류마티스 관절염 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter's Five Forces 분석
    • 공급 기업의 교섭력(중)
    • 신규 참여업체의 위협(저)
    • 구매자의 교섭력(중)
    • 대체품의 위협(중)
    • 기존 기업간 경쟁력(고)
  • PESTEL 분석
  • 류마티스 관절염 시장 업계 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 류마티스 관절염 시장 : 약제 유형별

  • 주요 조사 결과
  • 서론
    • 약제 유형별 : 2018-2030년
  • 의약품
    • 의약품별, 지역별 : 2018-2030년
  • NSAID
    • NSAID별, 지역별 : 2018-2030년
  • 진통제
    • 진통제별, 지역별 : 2018-2030년
  • DMARD
    • DMARD별, 지역별 : 2018-2030년
  • 글루코코르티코이드
    • 글루코코르티코이드별, 지역별 : 2018-2030년
  • 바이오의약품
    • 바이오의약품별, 지역별 : 2018-2030년
  • 생물제제
    • 생물제제별, 지역별 : 2018-2030년
  • 바이오시밀러
    • 바이오시밀러별, 지역별 : 2018-2030년

제6장 세계의 류마티스 관절염 시장 : 유통 채널별

  • 주요 조사 결과
  • 서론
    • 유통 채널별 : 2018-2030년
  • 원내 약국
    • 원내 약국별, 지역별 : 2018-2030년
  • 소매 약국
    • 소매 약국별, 지역별 : 2018-2030년
  • 드러그스토어
    • 드러그스토어별, 지역별 : 2018-2030년

제7장 세계의 류마티스 관절염 시장 : 치료법별

  • 주요 조사 결과
  • 서론
    • 치료법별 : 2018-2030년
  • 대증요법
    • 대증요법별, 지역별 : 2018-2030년
  • 중간 코르티코스테로이드 요법
    • 중간 코르티코스테로이드 요법별, 지역별 : 2018-2030년
  • 줄기세포 요법/세포치료
    • 줄기세포 요법/세포치료별, 지역별 : 2018-2030년
  • 질환 조절성 항류마티스약(DMARD)
    • 질환 조절성 항류마티스약(DMARD)별, 지역별 : 2018-2030년
  • 기존형 DMARD
    • 기존형 DMARD별, 지역별 : 2018-2030년
  • 생물학적 DMARD
    • 생물학적 DMARD별, 지역별 : 2018-2030년

제8장 세계의 류마티스 관절염 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 류마티스 관절염 시장 평가 - 지역별 : 2018-2030년
  • 북미
    • 약제 유형별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유통 채널별 : 2018-2030년
    • 미국
    • 캐나다
  • 유럽
    • 약제 유형별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유통 채널별 : 2018-2030년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
  • 아시아태평양
    • 약제 유형별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유통 채널별 : 2018-2030년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
  • 중동·아프리카
    • 약제 유형별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유통 채널별 : 2018-2030년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
  • 라틴아메리카
    • 약제 유형별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유통 채널별 : 2018-2030년
    • 멕시코
    • 브라질
    • 아르헨티나

제9장 경쟁 구도

  • 사업 확장과 인수 분석
    • 사업 확장
    • 인수
  • 제휴/협업/협정/전시회

제10장 기업 개요

  • AbbVie Incorporation
  • Amgen Corporation
  • Amneal Pharmaceuticals LLC
  • Bristol-Myers Squibb Company
  • Cipla, Inc
  • Dr. Reddy's Laboratories
  • Norbrook Laboratories Ltd
  • Roxane Laboratories Inc
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Sobi Inc
  • Teva Pharmaceuticals, Inc
KSA 22.11.18

The global rheumatoid arthritis market size is expected to reach USD 33.30 billion by 2030, according to a new study by Polaris Market Research. The report "Rheumatoid Arthritis Market Share, Size, Trends, Industry Analysis Report, By Therapy (Cell Therapy, DMARD, Symptomatic Treatment, Intermediate Corticosteroid Therapies); By Distribution Channel; By Drug Type; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market is being fueled by a rise in the number of arthritis and associated joint problems. Rheumatoid arthritis is on the rise as a result of the shift to an unhealthy lifestyle, rising metabolic disorders & age, family history of joint diseases, and increased obesity. As per the Centers for Disease Control and Prevention (CDC), millions of people in the US have severe pain due to arthritis each year. 15 million adults with arthritis report having severe joint pain as a result of their disease.

To strengthen their position in this market, manufacturers are concentrating on partnerships with other competitors. In January 2022, the Queen Mary University of London and Exagen Inc. announced a partnership and exclusive license agreement. The collaboration's main goal is to customize the choice of treatment agents for Rheumatoid Arthritis (RA) patients by developing and refining patent-pending personalized medicine techniques based on RNA expression patterns.

Both parties will work together to develop the patent-pending assays, which will eventually lead to the commercialization of cutting-edge molecular assays that divide patients into groups based on the expression of particular genes in synovial tissue biopsies. Thus, these factors are assisting the market growth over the forecast period.

Furthermore, in comparison to the general population, women have a higher risk of developing certain autoimmune illnesses. For instance, as per the Department of Health & Human Services (HHS) in the US, RA is the fourth-largest cause of disability among women in the US and are the eighth-leading cause of mortality for women between the ages of 15 and 64. The prevalence of rheumatoid arthritis (RA) in the US is high due to which the demand and adoption of treatment have increased. In rheumatoid arthritis (RA), the immune system attacks the joint.

The development of complex biologics, rising purchasing power, rising healthcare costs, and improved accessibility to high-quality medicines for middle-class and low-income families globally are all important causes. On the other hand, the global market is anticipated to grow swiftly and change the market picture due to improved treatment for early treatment and screening of rheumatoid arthritis. As a result, the global market for rheumatoid arthritis medications is seeing rapid growth, which is opening up attractive potential.

Rheumatoid Arthritis Market Report Highlights

The online pharmacy segment is anticipated to grow at a significant CAGR over the forecast period. This can be attributed to the expanding e-commerce market and rising popularity of online drug sales following the COVID-19 virus spread. The growing use of smartphones and the internet is helping the segmental expansion even further.

NSAIDs drug segment accounted for a major share of the global revenue share. Non-steroidal anti-inflammatory drugs (NSAIDs) are among them and are frequently used to treat the symptoms of rheumatic disorders, which are characterized by a variety of acute pain symptoms and long-term musculoskeletal discomfort. These medications' main result is to lessen acute inflammation, which lessens pain and enhances overall performance.

Asia Pacific is expected to grow at a highest CAGR over the projected period. Due to the substantial population base vulnerable to RA, the growth of the R&D sector, and the rising adoption of RA drugs, the region offers profitable positions for major players operating in the market

The global market players with a global presence includes AbbVie Incorporation, Sun Pharmaceutical Industries Ltd., Sobi Inc., and Teva Pharmaceuticals, Inc.

Polaris Market Research has segmented the rheumatoid arthritis market report based on drug type, distribution channel, therapy, and region:

Rheumatoid Arthritis, Therapy Outlook (Revenue - USD Billion, 2018 - 2030)

Symptomatic Treatment

Intermediate Corticosteroid Therapies

Stem Cell Therapy/ Cell Therapy

Disease Modifying Anti-rheumatic Drug (DMARD)

Conventional DMARDs

Biological DMARDs

Rheumatoid Arthritis, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Rheumatoid Arthritis, Drug Type Outlook (Revenue - USD Billion, 2018 - 2030)

Pharmaceuticals

NSAIDs

Analgesics

DMARDs

Glucocorticoids

Biopharmaceuticals

Biologics

Biosimilars

Rheumatoid Arthritis, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Rheumatoid Arthritis Market Insights

  • 4.1. Rheumatoid Arthritis - Industry Snapshot
  • 4.2. Rheumatoid Arthritis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising FDA approvals for the treatment of rheumatoid arthritis
      • 4.2.1.2. Increase in healthcare expenditure worldwide
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of access to treatment of rheumatoid arthritis in underdeveloped countries
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Rheumatoid Arthritis Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Rheumatoid Arthritis Market, by Drug Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
  • 5.3. Pharmaceuticals
    • 5.3.1. Global Rheumatoid Arthritis Market, by Pharmaceuticals, by Region, 2018 - 2030 (USD Billion)
  • 5.4. NSAIDs
    • 5.4.1. Global Rheumatoid Arthritis Market, by NSAIDs, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Analgesics
    • 5.5.1. Global Rheumatoid Arthritis Market, by Analgesics, by Region, 2018 - 2030 (USD Billion)
  • 5.6. DMARDs
    • 5.6.1. Global Rheumatoid Arthritis Market, by DMARDs, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Glucocorticoids
    • 5.7.1. Global Rheumatoid Arthritis Market, by Glucocorticoids, by Region, 2018 - 2030 (USD Billion)
  • 5.8. Biopharmaceuticals
    • 5.8.1. Global Rheumatoid Arthritis Market, by Biopharmaceuticals, by Region, 2018 - 2030 (USD Billion)
  • 5.9. Biologics
    • 5.9.1. Global Rheumatoid Arthritis Market, by Biologics, by Region, 2018 - 2030 (USD Billion)
  • 5.10. Biosimilars
    • 5.10.1. Global Rheumatoid Arthritis Market, by Biosimilars, by Region, 2018 - 2030 (USD Billion)

6. Global Rheumatoid Arthritis Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Rheumatoid Arthritis Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Rheumatoid Arthritis Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Drug Stores
    • 6.5.1. Global Rheumatoid Arthritis Market, by Drug Stores, by Region, 2018 - 2030 (USD Billion)

7. Global Rheumatoid Arthritis Market, by Therapy

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
  • 7.3. Symptomatic Treatment
    • 7.3.1. Global Rheumatoid Arthritis Market, by Symptomatic Treatment, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Intermediate Corticosteroid Therapies
    • 7.4.1. Global Rheumatoid Arthritis Market, by Intermediate Corticosteroid Therapies, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Stem Cell Therapy/ Cell Therapy
    • 7.5.1. Global Rheumatoid Arthritis Market, by Stem Cell Therapy/ Cell Therapy, by Region, 2018 - 2030 (USD Billion)
  • 7.6. Disease Modifying Anti-rheumatic Drug (DMARD)
    • 7.6.1. Global Rheumatoid Arthritis Market, by Disease Modifying Anti-rheumatic Drug (DMARD), by Region, 2018 - 2030 (USD Billion)
  • 7.7. Conventional DMARDs
    • 7.7.1. Global Rheumatoid Arthritis Market, by Conventional DMARDs, by Region, 2018 - 2030 (USD Billion)
  • 7.8. Biological DMARDs
    • 7.8.1. Global Rheumatoid Arthritis Market, by Biological DMARDs, by Region, 2018 - 2030 (USD Billion)

8. Global Rheumatoid Arthritis Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Rheumatoid Arthritis Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Rheumatoid Arthritis Market - North America
    • 8.3.1. North America: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.3.4. Rheumatoid Arthritis Market - U.S.
      • 8.3.4.1. U.S.: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.3.5. Rheumatoid Arthritis Market - Canada
      • 8.3.5.1. Canada: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.4. Rheumatoid Arthritis Market - Europe
    • 8.4.1. Europe: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.4. Rheumatoid Arthritis Market - UK
      • 8.4.4.1. UK: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.5. Rheumatoid Arthritis Market - France
      • 8.4.5.1. France: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.6. Rheumatoid Arthritis Market - Germany
      • 8.4.6.1. Germany: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.7. Rheumatoid Arthritis Market - Italy
      • 8.4.7.1. Italy: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.8. Rheumatoid Arthritis Market - Spain
      • 8.4.8.1. Spain: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.9. Rheumatoid Arthritis Market - Netherlands
      • 8.4.9.1. Netherlands: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.10. Rheumatoid Arthritis Market - Russia
      • 8.4.10.1. Russia: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.5. Rheumatoid Arthritis Market - Asia Pacific
    • 8.5.1. Asia Pacific: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.4. Rheumatoid Arthritis Market - China
      • 8.5.4.1. China: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.5. Rheumatoid Arthritis Market - India
      • 8.5.5.1. India: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.6. Rheumatoid Arthritis Market - Malaysia
      • 8.5.6.1. Malaysia: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.7. Rheumatoid Arthritis Market - Japan
      • 8.5.7.1. Japan: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.8. Rheumatoid Arthritis Market - Indonesia
      • 8.5.8.1. Indonesia: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.9. Rheumatoid Arthritis Market - South Korea
      • 8.5.9.1. South Korea: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.6. Rheumatoid Arthritis Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.4. Rheumatoid Arthritis Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.5. Rheumatoid Arthritis Market - UAE
      • 8.6.5.1. UAE: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.6. Rheumatoid Arthritis Market - Israel
      • 8.6.6.1. Israel: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.7. Rheumatoid Arthritis Market - South Africa
      • 8.6.7.1. South Africa: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.7. Rheumatoid Arthritis Market - Latin America
    • 8.7.1. Latin America: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.4. Rheumatoid Arthritis Market - Mexico
      • 8.7.4.1. Mexico: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.5. Rheumatoid Arthritis Market - Brazil
      • 8.7.5.1. Brazil: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.6. Rheumatoid Arthritis Market - Argentina
      • 8.7.6.1. Argentina: Rheumatoid Arthritis Market, by Drug Type, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Rheumatoid Arthritis Market, by Therapy, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Rheumatoid Arthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Incorporation
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Amgen Corporation
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Amneal Pharmaceuticals LLC
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bristol-Myers Squibb Company
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Cipla, Inc
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Dr. Reddy's Laboratories
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Norbrook Laboratories Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Roxane Laboratories Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Pfizer Inc
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sanofi SA
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Sun Pharmaceutical Industries Ltd
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Sobi Inc
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Teva Pharmaceuticals, Inc
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제